New drug aims to shield kidneys during heart surgery

NCT ID NCT07164833

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tests an experimental drug called BX-001N to see if it can prevent acute kidney injury and serious kidney problems after heart surgery. About 40 adults with aortic disease who need heart surgery with circulatory arrest will take part. Half will get the drug and half a placebo, and researchers will monitor kidney function and health outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIA-REPERFUSION INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Korea University Anam Hospital

    NOT_YET_RECRUITING

    Seoul, 02841, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Pusan National University Yangsan Hospital

    NOT_YET_RECRUITING

    Yangsan, 50612, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seoul Asan Medical center

    NOT_YET_RECRUITING

    Seoul, 05505, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Severance Hospital

    NOT_YET_RECRUITING

    Seoul, 03722, South Korea

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.